Royal Bank of Canada reduced its position in Esperion Therapeutics Inc (NASDAQ:ESPR) by 47.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,507 shares of the biopharmaceutical company’s stock after selling 2,294 shares during the quarter. Royal Bank of Canada’s holdings in Esperion Therapeutics were worth $79,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ESPR. Acadian Asset Management LLC purchased a new position in Esperion Therapeutics in the first quarter worth $43,000. PNC Financial Services Group Inc. grew its holdings in Esperion Therapeutics by 32,833.3% in the first quarter. PNC Financial Services Group Inc. now owns 1,976 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,970 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Esperion Therapeutics by 59.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,159 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 808 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its holdings in Esperion Therapeutics by 68.1% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,348 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 546 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Esperion Therapeutics in the first quarter worth $186,000.
A number of brokerages have recently weighed in on ESPR. Credit Suisse Group began coverage on shares of Esperion Therapeutics in a report on Monday, June 29th. They set a “buy” rating and a $83.00 price objective on the stock. ValuEngine raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, April 21st. Stifel Nicolaus reissued a “buy” rating and set a $75.00 price objective on shares of Esperion Therapeutics in a report on Friday, June 26th. Jefferies Financial Group dropped their price objective on shares of Esperion Therapeutics from $85.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Citigroup boosted their price objective on shares of Esperion Therapeutics from $46.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, May 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company’s stock. Esperion Therapeutics presently has a consensus rating of “Buy” and an average price target of $78.50.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($2.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.14) by $0.30. The business had revenue of $1.80 million during the quarter, compared to the consensus estimate of $0.39 million. Esperion Therapeutics had a negative net margin of 5,492.02% and a negative return on equity of 627.38%. The company’s revenue was down 98.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.07 earnings per share. Equities research analysts forecast that Esperion Therapeutics Inc will post -4.87 EPS for the current year.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Story: Momentum Indicators
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.